Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-09-2013 | Review

Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis

Authors: Xiaoying Li, Lianxi Qu, Yu Zhong, Yingjie Zhao, Hongyan Chen, Lu Daru

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2013

Abstract

Purpose

A variety of studies have been performed to elucidate the polymorphisms in promoter regions of matrix metalloproteinases (MMPs) associated with the risk of digestive cancers, and yet, results remain conflicting and heterogeneous. Thus, we undertook a systematic meta-analysis to determine the genetic susceptibility of MMPs to digestive cancers.

Methods

A computerized literature search was conducted in databases of PubMed, Embase, and ISI Web of Knowledge till October 2012 for any MMP genetic association study in oral squamous, gastric, esophageal, and colorectal carcinomas. Odds ratios (OR) and 95 % confidence interval (CI) were estimated for each gene under dominant and recessive models, and the heterogeneity between studies was assessed using Q test and I ² value. Overall and subgroup analysis according to anatomical sites and ethnicity was carried out. Statistical analysis was performed with Review Manager 5.0.

Results

A total of 40 eligible publications with 68 comparisons were included in this study. For MMP1 nt-1607, individuals with 2G state could increase risk of digestive cancers in total analysis (dominant: OR = 1.31, 95 % CI = 1.16–1.48, P < 0.00001; recessive: OR = 1.29, 95 % CI = 1.11–1.50, P = 0.0009). In the subgroup of tumor sites, significant associations were also observed in esophageal cancer and colorectal cancer under both genetic models. For MMP2 nt-1306, CT or TT carriers performed significant protection against digestive cancer in the dominant model (OR = 0.69, 95 % CI = 0.55–0.85, P = 0.0007) of the overall. In the subgroup analysis, significant association was found in esophageal cancer, with borderline effects in gastric cancer and oral squamous cell carcinoma. For MMP7 −181 A/G, significant association was observed under two genetic models in the overall (dominant: OR = 1.26, 95 % CI = 1.10–1.43, P = 0.0009; recessive: OR = 1.33, 95 % CI = 1.11–1.60, P = 0.002) and in the individual cancer subgroup of esophageal cancer and gastric cancer. For MMP9 −1,562 C/T, a borderline effect was found with digestive cancers in the total and stratified analysis of the colorectal cancer under dominant model. No association was observed in either the overall or subgroup analysis for MMP3 −1,171 5A/6A.

Conclusions

Our meta-analysis demonstrated the fact that polymorphisms in promoter regions of MMP genes might be related to the susceptibility of digestive cancers, with cancer development for MMP1 and MMP7, and a protection against cancer for MMP2 and MMP9. Further evidences with adequate sample sizes need to be conducted.

Available only for authorised users

Agudo A, Bonet C, Travier N, Gonzalez CA, Vineis P, Bueno-de-Mesquita HB, Trichopoulos D, Boffetta P, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Lukanova A, Schutze M, Boeing H, Tjonneland A, Halkjaer J, Overvad K, Dahm CC, Quiros JR, Sanchez MJ, Larranaga N, Navarro C, Ardanaz E, Khaw KT, Wareham NJ, Key TJ, Allen NE, Trichopoulou A, Lagiou P, Palli D, Sieri S, Tumino R, Panico S, Boshuizen H, Buchner FL, Peeters PH, Borgquist S, Almquist M, Hallmans G, Johansson I, Gram IT, Lund E, Weiderpass E, Romieu I, Riboli E (2012) Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study. J Clin Oncol 30(36):4550–4557

Ahmed MM, Mohammed SH (2011) Matrix metalloproteinases 2 and 9 in situ mRNA expression in colorectal tumors from Iraqi patients. Indian J Pathol Microbiol 54(1):7–14PubMedCrossRef

Alakus H, Afriani N, Warnecke-Eberz U, Bollschweiler E, Fetzner U, Drebber U, Metzger R, Holscher AH, Monig SP (2010) Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. World J Surg 34(12):2853–2859PubMedCrossRef

Back M, Ketelhuth DF, Agewall S (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52(5):410–428PubMedCrossRef

Basu P, Sen U, Tyagi N, Tyagi SC (2010) Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function. Vasc Health Risk Manag 6:215–228PubMed

Biondi ML, Turri O, Leviti S, Seminati R, Cecchini F, Bernini M, Ghilardi G, Guagnellini E (2000) MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem 46(12):2023–2024PubMed

Bissell MJ, Kenny PA, Radisky DC (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343–356PubMedCrossRef

Bourboulia D, Stetler-Stevenson WG (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20(3):161–168PubMedCrossRef

Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G (2009) Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 30(5):793–798PubMedCrossRef

Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477(1–2):267–283PubMedCrossRef

Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6(12):4823–4830PubMed

Burn J, Mathers J, Bishop DT (2013) Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res 191:157–183PubMedCrossRef

Chen XB, Chen GL, Liu JN, Yang JZ, Yu DK, Lin DX, Tan W (2009) Genetic polymorphisms in STK15 and MMP-2 associated susceptibility to esophageal cancer in Mongolian population. Zhonghua Yu Fang Yi Xue Za Zhi 43(7):559–564PubMed

Chen PS, Shih YW, Huang HC, Cheng HW (2011) Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS ONE 6(5):e20164PubMedCrossRef

Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, Asomaning K, Ma C, Xu W, Wang Z, Hooshmand S, Su L, Christiani DC, Liu G (2012) Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer 131(11):2478–2486PubMedCrossRef

de Lima JM, de Souza LG, da Silva ID, Forones NM (2009) E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer. Int J Biol Markers 24(2):99–106PubMed

DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105–114PubMedCrossRef

Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRef

Dziki L, Przybylowska K, Majsterek I, Trzcinski R, Mik M, Sygut A (2011) A/G polymorphism of the MMP-7 gene promoter region in colorectal cancer. Pol Przegl Chir 83(11):622–626PubMed

Elander N, Soderkvist P, Fransen K (2006) Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26(1B):791–795PubMed

Fang WL, Liang WB, He H, Zhu Y, Li SL, Gao LB, Zhang L (2010) Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population. DNA Cell Biol 29(11):657–661PubMedCrossRef

Gencer S, Cebeci A, Irmak-Yazicioglu MB (2011) Silencing of the MMP-3 gene by siRNA transfection in gastric cancer AGS cells. J Gastrointestin Liver Dis 20(1):19–26PubMed

Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, Scorza R (2001) Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 7(8):2344–2346PubMed

Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A (2012) Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 12:121PubMedCrossRef

Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber C, Hofelmayr A, Gattenlohner S, Otto C, Germer CT, von Rahden BH (2010) MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 8:99PubMedCrossRef

Haas SL, Ye W, Lohr JM (2012) Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care 15(5):457–467PubMedCrossRef

Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, Hazama S, Kitamura Y, Kamatani N, Oka M (2002) Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 102(5):526–529PubMedCrossRef

Itoh Y, Nagase H (2002) Matrix metalloproteinases in cancer. Essays Biochem 38:21–36PubMed

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Jin X, Kuang G, Wei LZ, Li Y, Wang R, Guo W, Wang N, Fang SM, Wen DG, Chen ZF, Zhang JH (2005) No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol 11(16):2385–2389PubMed

Kang MJ, Jung SA, Jung JM, Kim SE, Jung HK, Kim TH, Shim KN, Yi SY, Yoo K, Moon IH (2011) Associations between single nucleotide polymorphisms of MMP2, VEGF, and HIF1A genes and the risk of developing colorectal cancer. Anticancer Res 31(2):575–584PubMed

Kemik O, Kemik AS, Sumer A, Dulger AC, Adas M, Begenik H, Hasirci I, Yilmaz O, Purisa S, Kisli E, Tuzun S, Kotan C (2011) Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. World J Gastroenterol 17(16):2109–2112PubMedCrossRef

Kim J, Pyun JA, Cho SW, Lee K, Kwack K (2011a) Lymph node metastasis of gastric cancer is associated with the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2. DNA Cell Biol 30(12):1011–1017PubMedCrossRef

Kim JH, Pyun JA, Lee KJ, Cho SW, Kwack KB (2011b) Study on association between single nucleotide polymorphisms of MMP7, MMP8, MMP9 genes and development of gastric cancer and lymph node metastasis. Korean J Gastroenterol 58(5):245–251PubMedCrossRef

Kontou N, Psaltopoulou T, Soupos N, Polychronopoulos E, Xinopoulos D, Linos A, Panagiotakos D (2012) Alcohol consumption and colorectal cancer in a Mediterranean population: a case-control study. Dis Colon Rectum 55(6):703–710PubMedCrossRef

Kouhkan F, Motovali-Bashi M, Hojati Z (2008) The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population. Cancer Invest 26(8):836–842PubMedCrossRef

Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW (2006) Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 95(6):744–751PubMedCrossRef

Lemaitre V, D’Armiento J (2006) Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 78(1):1–10PubMedCrossRef

Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ (2010) Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep 37(1):197–205PubMedCrossRef

Lievre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellie C, Laurent-Puig P (2006) Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 6:270PubMedCrossRef

Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ, Chang KW (2004a) Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med 33(6):323–326PubMedCrossRef

Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW (2004b) Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 33(7):405–409PubMedCrossRef

Liu D, Duan W, Guo H, Xu X, Bai Y (2011a) Meta-analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer. Int J Colorectal Dis 26(9):1099–1105PubMedCrossRef

Liu L, Wu C, Wang Y, Zhong R, Wang F, Zhang X, Duan S, Lou J, Yu D, Tan W, Yuan J, Wu T, Nie S, Miao X, Lin D (2011b) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32(3):336–342PubMedCrossRef

Lopez-Otin C, Palavalli LH, Samuels Y (2009) Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 8(22):3657–3662PubMedCrossRef

Lubin JH, Cook MB, Pandeya N, Vaughan TL, Abnet CC, Giffen C, Webb PM, Murray LJ, Casson AG, Risch HA, Ye W, Kamangar F, Bernstein L, Sharp L, Nyren O, Gammon MD, Corley DA, Wu AH, Brown LM, Chow WH, Ward MH, Freedman ND, Whiteman DC (2012) The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett’s Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol 36(3):306–316PubMedCrossRef

Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696–1701PubMedCrossRef

Malik MA, Sharma KL, Zargar SA, Mittal B (2011a) Association of matrix metalloproteinase-7 (-181A > G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir valley. Saudi J Gastroenterol 17(5):301–306PubMedCrossRef

Malik MA, Zargar SA, Mittal B (2011b) Role of the metalloproteinase-7 (181A > G) polymorphism in gastric cancer susceptibility: a case control study in Kashmir valley. Asian Pac J Cancer Prev 12(1):73–76PubMed

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

Matsumura S, Oue N, Kitadai Y, Chayama K, Yoshida K, Yamaguchi Y, Toge T, Imai K, Nakachi K, Yasui W (2004) A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol 130(5):259–265PubMedCrossRef

Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W (2005) A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131(1):19–25PubMedCrossRef

McColgan P, Sharma P (2009) Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 125(6):1473–1478PubMedCrossRef

Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D (2003) A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63(14):3987–3990PubMed

Mroczko B, Lukaszewicz-Zajac M, Gryko M, Kedra B, Szmitkowski M (2011) Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol 49(1):125–131PubMed

Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R (2003) A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 200(1):49–55PubMedCrossRef

Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, Kubota T, Itagaki M, Shingaki S, Ohnishi M, Kurita H, Katsura K, Saito C, Yoshie H, Takagi R (2007) The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer 7:187PubMedCrossRef

Oc P, Leksrisakul P, Sangruchi S (2006) A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 118(10):2548–2553CrossRef

Ohtani H, Maeda N, Murawaki Y (2009) Functional polymorphisms in the promoter regions of matrix metalloproteinase-2,-3,-7,-9 and TNF-alpha genes, and the risk of colorectal neoplasm in Japanese. Yonago Acta Medica 52(1):47–56

Park KS, Kim SJ, Kim KH, Kim JC (2011) Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 26(2):391–397PubMedCrossRef

Pellegrini ML, Argibay P, Gomez DE (2011) Genetics and epigenetics of colorectal cancer. Acta Gastroenterol Latinoam 41(3):247–261PubMed

Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276(10):7549–7558PubMedCrossRef

Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297PubMedCrossRef

Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58(23):5321–5325PubMed

Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L (2007) TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet 172(1):38–44PubMedCrossRef

Srivastava P, Kapoor R, Mittal RD (2009) Influence of matrix metalloproteinase gene polymorphisms in healthy North Indians compared to variations in other ethnic groups worldwide. Asian Pac J Cancer Prev 10(6):1127–1130PubMed

Srivastava P, Gangwar R, Kapoor R, Mittal RD (2010) Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers 29(1):37–46PubMedCrossRef

Strohle A, Maike W, Hahn A (2007) Nutrition and colorectal cancer. Med Monatsschr Pharm 30(1):25–32PubMed

Sugimoto M, Furuta T, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Hishida A (2008) Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J Gastroenterol 43(10):751–761PubMedCrossRef

Surlin V, Ioana M, Plesea IE (2011) Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer. Rom J Morphol Embryol 52(1 Suppl):231–236PubMed

Tang FY, Pai MH, Wang XD (2011) Consumption of lycopene inhibits the growth and progression of colon cancer in a mouse xenograft model. J Agric Food Chem 59(16):9011–9021PubMedCrossRef

Tower GB, Coon CI, Belguise K, Chalbos D, Brinckerhoff CE (2003) Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter. Eur J Biochem 270(20):4216–4225PubMedCrossRef

Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT (2007) Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 36(7):409–414PubMedCrossRef

Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, Spyridonidou S, Derka S, Vassiliou S, Nkenke E, Patsouris E (2009) Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 45(3):247–253PubMedCrossRef

Vogelaar IP, van der Post RS, Bisseling TM, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N (2012) Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract 10(1):18PubMedCrossRef

Woo M, Park K, Nam J, Kim JC (2007) Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 22(7):1064–1070PubMedCrossRef

Wu CY, Wu MS, Chen YJ, Chen CJ, Chen HP, Shun CT, Chen GH, Huang SP, Lin JT (2007) Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 43(4):799–808PubMedCrossRef

Wyatt CA, Coon CI, Gibson JJ, Brinckerhoff CE (2002) Potential for the 2G single nucleotide polymorphism in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res 62(24):7200–7202PubMed

Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, Luo Y, Zhang X (2007) Matrix metalloproteinase-9-1562C > T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol 13(34):4626–4629PubMed

Xu E, Lai M, Lu B, Xing X, Huang Q (2006a) No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese. Dis Colon Rectum 49(9):1439–1444PubMedCrossRef

Xu EP, Huang Q, Lu BJ, Xing XM, Lai MD (2006b) The correlation between polymorphisms of matrix metalloproteinase-2 and -9 genes and colorectal cancer of Chinese patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(1):78–81PubMed

Yan C, Boyd DD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211(1):19–26PubMedCrossRef

Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19(7):623–629PubMedCrossRef

Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64(20):7622–7628PubMedCrossRef

Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S (1999) Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 105(5):418–423PubMedCrossRef

Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, Wang N, Wang Y, Wen D, Wei L, Kuang G, Dong Z (2004a) The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 25(12):2519–2524PubMedCrossRef

Zhang XM, Miao XP, Xiong P, Yu CY, Tan W, Qu SN, Sun T, Zhou YF, Lin DX (2004b) Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population. Ai Zheng 23(11):1233–1237PubMed

Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, Guo W, Wang Y, Wen D, Wei L, Dong Z, Kuang G (2005) The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 26(10):1748–1753PubMedCrossRef

Zhang WQ, Lin H, Zhou YA, Wang YJ, Cheng QS (2006) Association of MMP1 -1607(1G > 2G)single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(3):313–315PubMed

Zhang LF, Mi YY, Cao Q, Wang W, Qin C, Wei JF, Zhou YJ, Li YF, Tang M, Liu WM, Zhang W, Zou JG (2012) Update analysis of studies on the MMP-9 -1562 C > T polymorphism and cancer risk. Mol Biol Rep 39(4):3435–3441PubMedCrossRef

Zhou J, Brinckerhoff C, Lubert S, Yang K, Saini J, Hooke J, Mural R, Shriver C, Somiari S (2011a) Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors. Cancer Invest 29(9):599–607PubMedCrossRef

Zhou JH, Zhang B, Kernstine KH, Zhong L (2011b) Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 17(10):1373–1378PubMedCrossRef

Title: Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis
Authors: Xiaoying Li
Lianxi Qu
Yu Zhong
Yingjie Zhao
Hongyan Chen
Lu Daru
Publication date: 01-09-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 9/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1446-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer

Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma

Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis

RETRACTED ARTICLE: Randomized clinical trial of arginine-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing gastric cancer surgery

A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically

Complementary medicine in guidelines of the German Guideline Program in Oncology: comparison of the evidence base between complementary and conventional therapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials